Lundbeck obtains rights to breakthrough research in Alzheimer’s disease
H. Lundbeck A/S (Lundbeck) has entered into an agreement with biotech company ImmunoBrain Checkpoint, Inc. (IBC) for the rights to IBC’s groundbreaking research in the treatment of Alzheimer’s disease. The research focuses on modifying antibodies currently used in cancer treatment for use in treating the debilitating brain disease which 48 million patients are estimated to suffer from[i]. A number expected to rapidly increase in the future.“IBC has a unique and innovative approach to this highly complex disease and the data generated until now are highly promising. We are delighted to take